Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søk Study Connect
  • NCT06869551

Recruiting

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis - IM011-1071

Oppdatert: 17 juni, 2025   |   ClinicalTrials.gov

Utskriftsvennlig Sammendrag

VURDERER DU DENNE STUDIEN?
Skriv ut denne siden og studieveiledningen for å hjelpe deg å snakke med legen din.
Bruk Veiledning for studiedeltakere til å navigere gjennom deltakerprosessen i en klinisk studie. Forstå viktige faktorer å vurdere før du bestemmer deg og motta spørsmål som du kan stille til helsepersonalet ditt.
Skriv ut denne siden IM011-1071
Last ned Veiledning for studiedeltakere

VELG SPRÅK

Vis detaljer

  • Phase 3

    Fase

  • Kjønn

  • 5-17

    Aldersgruppe

  • 24

    Sted(er)

  • Recruiting

Behandlingsalternativer

Studiearmer
TILDELT INTERVENSJON
Experimental: Arm A
Drug: Deucravacitinib
Placebo Comparator: Arm B
Drug: Deucravacitinib Other: Placebo

Nøkkelkriterier for kvalifikasjon

Inclusion Criteria - Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). - Participants must have at least three joints that are affected by arthritis. - Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria - Participants must not have been diagnosed with JPsA before 5 years of age. - Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, - Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months. - Other protocol-defined Inclusion/Exclusion criteria apply.

Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon

MLTNO2000046